← All publications

Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung Cancer

Milgram BC, Borrelli DR, Brooijmans N, … Guzman-Perez A · J Med Chem 2025 · J Med Chem 68(3):2403-2421

EGFR/HER2 exon 20 mutants Tyrosine kinase Covalent inhibitor kineticsInhibitor discovery & SARSelectivity & kinome profiling PhosphoSens

Read the paper View on PubMed

More publications on EGFR/HER2

STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models

Pagliarini RA, Henderson JA, Milgram BC, … Stuart DD · Clin Cancer Res 2025

AssayQuant Technologies logo

 

 

260 Cedar Hill Street
Marlboro MA 01752

Phone: +1 (508) 804-3155

      

© 2026 AssayQuant Technologies, Inc. - All Rights Reserved - Privacy Policy - Terms & Conditions - FCOI